RxDoctor Payments Data

Tearrah Conerly

Family · Meridian, MSNPI 1174878193

Payments from drug & device makers

$1,898in general payments, 2019–2025

Across 71 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$530
  • Teva Pharmaceuticals USA, Inc.$335
  • Otsuka America Pharmaceutical, Inc.$226
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$218
  • Alkermes, Inc.$210
  • Neurocrine Biosciences, Inc.$124
  • plus $255 from 4 others

What the payments were for

  • Food & beverage$1,898100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,898 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$57,061
Medicare patients
293
Services billed
869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$32,048
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl129$15,084
EntrestoSacubitril/Valsartan19$14,324
TrulicityDulaglutide12$11,266
EliquisApixaban11$5,980
BrilintaTicagrelor13$5,936
Albuterol Sulfate HfaAlbuterol Sulfate43$1,431
Ibuprofen98$875
Omeprazole81$760
Amlodipine Besylate161$730
Gabapentin83$713
Potassium Chloride53$577
Oxcarbazepine21$532
Divalproex Sodium22$343
Metformin Hcl71$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$57$32,04827 claims
AstraZenecaBrilinta$97$5,93613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →